PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 26.2

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.25M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-05 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

+1.35 (+2.01%)

USD 10.78B
DOCS Doximity Inc

+0.35 (+0.63%)

USD 9.97B
WEAV Weave Communications Inc

+0.23 (+1.44%)

USD 1.13B
MPLN MultiPlan Corporation

-1.76 (-12.39%)

USD 0.23B
AMWL American Well Corp

+0.07 (+0.94%)

USD 0.11B
OWLT Owlet Inc

+0.05 (+1.10%)

USD 0.08B
TDOC Teladoc Inc

+0.41 (+4.31%)

N/A
FOXO FOXO Technologies Inc.

-0.02 (-6.00%)

N/A
EVH Evolent Health Inc

+0.12 (+1.01%)

N/A
VEEV Veeva Systems Inc Class A

-0.16 (-0.08%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.13% 73% C 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.13% 73% C 90% A-
Trailing 12 Months  
Capital Gain 17.44% 80% B- 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.44% 80% B- 67% D+
Trailing 5 Years  
Capital Gain -3.82% 50% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.82% 50% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain 10.96% 70% C- 67% D+
Dividend Return 10.96% 70% C- 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.63% 60% D- 14% F
Risk Adjusted Return 16.46% 80% B- 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector